Does a MitraClip procedure cause elevated Brain Natriuretic Peptide (BNP) levels?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: September 26, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Effect of MitraClip Procedure on BNP Levels

Yes, the MitraClip procedure typically causes an initial elevation in BNP levels, but successful treatment leads to significant reduction in BNP/NT-proBNP levels over time in most patients.

Initial BNP Response After MitraClip

The MitraClip procedure has a biphasic effect on BNP levels:

  • Immediate post-procedure: BNP levels often increase transiently due to:

    • Procedural stress on the heart
    • Inflammatory response to the intervention
    • Temporary hemodynamic changes during clip placement
  • Medium to long-term (3-6 months): In successful cases, BNP levels typically decrease significantly compared to baseline values 1, 2

Evidence for BNP Reduction After MitraClip

Research demonstrates that successful MitraClip placement leads to significant reductions in natriuretic peptide levels:

  • A study examining NT-proBNP response after MitraClip showed mean levels decreased from 6,117 pg/mL at baseline to 4,143 pg/mL at 6 months post-procedure (p < 0.001) 1

  • Another study demonstrated significant reductions in median NT-proBNP levels from 3,923 pg/mL to 2,636 pg/mL after MitraClip implantation (p = 0.02) 2

  • In patients with functional mitral regurgitation, higher preoperative pro-BNP levels (≥1,600 pg/ml) were identified as an independent risk factor for mortality at follow-up 3

Factors Affecting BNP Response After MitraClip

Not all patients show the same degree of BNP reduction after MitraClip. Key factors affecting BNP response include:

  • Right ventricular dysfunction: Patients with right ventricular systolic dysfunction (TAPSE <15 mm) are more likely to be NT-proBNP non-responders 1

  • Diabetes mellitus: Diabetes is an independent determinant of poor NT-proBNP response after MitraClip 1

  • Atrial fibrillation: More common in non-responders to MitraClip therapy 1

  • Baseline NT-proBNP levels: Very high baseline levels (>5,000 pg/mL) may predict less robust response 1

Clinical Significance of BNP Changes After MitraClip

The BNP response after MitraClip has important clinical implications:

  • A decrease in BNP >30% in response to heart failure treatment generally indicates a good prognosis 4

  • NT-proBNP responders (defined as >30% reduction at 6 months) tend to have better clinical outcomes 1

  • BNP reduction correlates with:

    • Improved left ventricular remodeling
    • Reduced tricuspid regurgitation pressure gradient
    • Decreased left ventricular end-diastolic volume 2, 5

Monitoring BNP After MitraClip

When interpreting BNP levels after MitraClip:

  • Serial measurements are more valuable than single readings 4

  • BNP should be interpreted alongside clinical status and echocardiographic findings

  • Non-cardiac factors that can affect BNP interpretation include:

    • Renal dysfunction
    • Age
    • Obesity (may lower BNP)
    • Hydration status 4

Clinical Implications

For patients undergoing MitraClip:

  • An initial rise in BNP immediately post-procedure should not necessarily be interpreted as treatment failure

  • Failure to see BNP reduction by 3-6 months may indicate suboptimal response and should prompt careful clinical reassessment

  • Patients with right ventricular dysfunction and diabetes should be monitored more closely as they may have less robust BNP response

  • BNP monitoring can help identify patients who may benefit from additional heart failure therapies or consideration for advanced options like heart transplantation 6

References

Research

MitraClip in CRT non-responders with severe mitral regurgitation.

International journal of cardiology, 2014

Research

Clinical outcomes of MitraClip for the treatment of functional mitral regurgitation.

EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology, 2014

Guideline

Heart Failure Management

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

MitraClip in secondary mitral regurgitation as a bridge to heart transplantation: 1-year outcomes from the International MitraBridge Registry.

The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation, 2020

Related Questions

What is the best algorithm for referring patients for MitraClip (percutaneous mitral valve repair) as a non-invasive cardiologist (Non-Invasive Cardiology)?
Should a 63-year-old male with Heart Failure with Reduced Ejection Fraction (HFrEF) (Ejection Fraction 15-20%), Non-Ischemic Cardiomyopathy (NICM), Left Ventricular End-Diastolic Diameter (LVEDD) 7.4cm, severe Mitral Regurgitation (MR), and multiple comorbidities, including Chronic Kidney Disease (CKD) stage 3b, Hypertension (HTN), Hyperlipidemia (HLD), and malnutrition, be considered for a MitraClip procedure?
Should a 63-year-old male with Heart Failure with Reduced Ejection Fraction (HFrEF) (Ejection Fraction 15-20%), Non-Ischemic Cardiomyopathy (NICM), Left Ventricular End-Diastolic Diameter (LVEDD) 7.4cm, history of Cerebrovascular Accident (CVA), Chronic Kidney Disease (CKD) stage 3b, Hypertension (HTN), Hyperlipidemia (HLD), and severe Mitral Regurgitation (MR) be considered for a MitraClip procedure?
Should a 63-year-old male with Heart Failure with Reduced Ejection Fraction (HFrEF) (Diagnosed in 2023, Ejection Fraction 15-20%, Non-Ischemic Cardiomyopathy (NICM), Left Ventricular End-Diastolic Diameter (LVEDD) 7.4cm), history of Cerebrovascular Accident (CVA) (Right Middle Cerebral Artery (R-MCA), Left Hemiplegia, 2023), Chronic Kidney Disease (CKD) (Stage 3b), Hypertension (HTN), Hyperlipidemia (HLD), Right Lower Lobe (RLL) nodule, and malnutrition, who has undergone multiple hospitalizations for Acute Decompensated Heart Failure (ADHF) and is currently on Carvedilol (Beta Blocker) 3.125 mg twice daily, Jardiance (Empagliflozin) 10 mg daily, Valsartan (Angiotensin II Receptor Blocker) 20 mg twice daily, Spironolactone (Aldosterone Antagonist) 12.5 mg daily, and Atorvastatin (HMG-CoA Reductase Inhibitor) 80 mg daily, with significant Left Ventricular (LV) dysfunction, severe Mitral Regurgitation (MR), and unable to tolerate further Guideline-Directed Medical Therapy (GDMT) due to hypotension, be considered for a MitraClip procedure?
How to evaluate and manage motor and neurological reflexes?
What is the cause and treatment for a single blister rash?
What is a recommended diet chart for a healthy adult?
What are the hallmarks of pancreatogenic diabetes?
What are the signs and symptoms of facial nerve compression by a large pleomorphic adenoma of the right parotid gland?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.